Navigation Links
DURECT Appoints Dr. Joseph Stauffer as Chief Medical Officer and Executive Vice President, Corporate Strategy
Date:6/16/2009

CUPERTINO, Calif., June 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Joseph Stauffer has joined DURECT as Chief Medical Officer and Executive Vice President, Corporate Strategy.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

"Dr. Stauffer's successful leadership of clinical research and medical affairs for pain products while at Alpharma and Abbott, and first-hand experience with the regulatory approval process gained during his tenure at the U.S. Food and Drug Administration (FDA), is an ideal fit for DURECT's pipeline of acute, chronic, neuropathic and post-surgical pain products," stated James E. Brown, President and CEO of DURECT Corporation. "We're looking forward to the impact he will have on the development of POSIDUR(TM), TRANSDUR(TM)-Sufentanil, ELADUR(TM) and other programs."

Dr. Stauffer was at Alpharma Inc. from 2004 to 2009, where his latest position prior to the acquisition of Alpharma by King Pharmaceuticals was as Chief Medical Officer and Senior Vice President of Clinical Research & Medical Affairs. His responsibilities at Alpharma included oversight of all clinical pharmacology, clinical development, pharmacovigilance, medical affairs, risk management and health outcomes/pharmacoeconomics. Prior to joining Alpharma, Dr. Stauffer was employed at Abbott Laboratories from 2002 to 2004 as Global Medical Director for Pain Therapeutics. In that role, he was responsible for Phase I-III trials for Vicodin, Vicoprofen, Dilaudid, as well as novel compounds targeting neuropathic pain. Prior to Abbott, he worked at the FDA from 2000 to 2002 as a Medical Review Officer in the Analgesic Division of the Center for Drug Evaluation and Research. While there, he reviewed Investigational New Drug (IND) Applications and New Drug Applications (NDAs) for opiate, non-opiate, anti-inflammatory, and novel pain compounds.

Dr. Stauffer is a founding member of the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT). This on-going collaboration between pharma, FDA, NIH, academia and patient advocacy groups helps to develop core domains and outcomes for chronic pain clinical trials. Dr. Stauffer graduated from the Philadelphia College of Osteopathic Medicine and completed residency training in Anesthesiology at the Johns Hopkins University Hospital, where he is currently an Adjunct Assistant Professor in the Department of Anesthesiology and Critical Care Medicine. Dr. Stauffer is a veteran of the U.S. Navy, honorably discharged as a Lieutenant Commander after serving eight years as a Naval Medical Officer. He will complete his MBA in September 2009 as part of the TRIUM Global Executive MBA Program, a joint degree granted by NYU Stern School of Business, HEC School of Management (Paris) and the London School of Economics and Political Science.

"I should also note that Dr. Peter Langecker, DURECT's former Chief Medical Officer, has resigned from DURECT Corporation to pursue another opportunity," stated James E. Brown. "We want to thank Peter for his service to DURECT and wish him well on his future endeavors."

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR(R), TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.


'/>"/>
SOURCE DURECT Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DURECT to Present at Merriman Curhan Fords Annual Investor Summit
2. DURECT to Present at UBS Global Life Sciences Conference
3. DURECT to Present at 2007 BIO Investor Forum
4. DURECT to Present at BIO CEO Investor Conference 2008
5. DURECT to Participate in Susquehanna Financial Healthcare Conference
6. DURECT to Participate in Cowen Annual Healthcare Conference
7. DURECT Provides Update on CHRONOGESIC(R) Research Program
8. DURECT to Participate in Morgan Stanley Global Healthcare Conference
9. DURECT Corporation Invites You to Join Its First Quarter 2008 Earnings Conference Call
10. DURECT Corporation Presenting at the 2008 UBS Global Generic and Specialty Pharmaceuticals Conference
11. DURECT Corporation Invites You to Join Its Second Quarter 2008 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... SunView Software’s ... Award for Innovation of the Year. , Each year, Pink Elephant recognizes ... an innovative approach to address a specific business problem or opportunity. The award highlights ...
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research ... Association of Music Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim ... has long been the gold standard for high-definition, in-ear earphones. This classic earphone ...
(Date:1/17/2017)... ... January 17, 2017 , ... Achieve TMS West, ... opening a new office in San Clemente, California this month. Achieve TMS West ... California, successfully treating individuals struggling with major depression. Depression impacts over 15 million ...
(Date:1/17/2017)... ... January 17, 2017 , ... Medic-CE ... EMS and firefighting professionals, has released four new continuing education courses as part ... taught live in an online classroom and meet the requirements of the National ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... lecture to primary eye care practitioners on the latest breakthroughs in the prevention, ... Semi-Annual Continuing Education Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Jan. 17, 2017  From the company that brought a full ... years ago, comes a new line of companion animal pet first ... leader in equine first aid, has developed two sizes of small ... , Inc. Featuring a small and a large ... and rodeo family, is not a newcomer to working with small ...
(Date:1/17/2017)... 2017  OrthoAccel ® Technologies, Inc. announces that ... published "The Effect of Vibration on Molar Distalization," a ... S. Jay Bowman , this prospective, peer-reviewed clinical ... SoftPulse Technology ® speeds up molar distalization rates ... number of days to move the upper molars into ...
(Date:1/17/2017)... , Jan 17, 2017 Research and ... in Healthcare Industry 2016-2020" report to their offering. ... The global fluoropolymer market ... during the period 2016-2020. Global Fluoropolymer Market in ... market analysis with inputs from industry experts. The report covers the ...
Breaking Medicine Technology: